Anika Therapeutics (ANIK) EBT Margin (2010 - 2026)
Anika Therapeutics (ANIK) reported EBT Margin of 16.28% for Q1 2026, down 150.0% year-over-year from 32.56% in Q1 2025, and down 145.27% quarter-over-quarter from 35.97% in Q4 2025.
Anika Therapeutics (ANIK) EBT Margin (2010 - 2026) Analysis & Trends
Anika Therapeutics (ANIK) has 17 years of EBT Margin data on file, last reported at 16.28% in Q1 2026.
- EBT Margin for Q1 2026 came in at 16.28%, down 150.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.01% (up 514.0% YoY), and the FY2025 annual result was 0.83%, up 423.0% from the prior year.
- EBT Margin eased to 16.28% in Q1 2026 per ANIK's latest filing, from 35.97% in the prior quarter.
- Over five years, EBT Margin peaked at 35.97% in Q4 2025 and troughed at 871.99% in Q4 2023.
- A 5-year average of 85.02% and a median of 10.11% in 2022 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2024: EBT Margin slumped 41670 bps in 2023, then soared 86782 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 455.29% in 2022, then sank by 92 bps to 871.99% in 2023, then soared by 100 bps to 4.17% in 2024, then soared by 963 bps to 35.97% in 2025, then tumbled by 145 bps to 16.28% in 2026.
- Business Quant data shows ANIK's EBT Margin at 16.28% in Q1 2026, 35.97% in Q4 2025, and 8.04% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 10.97% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 33.51% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 40.73% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 25.87% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 30.30% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 6.35% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -156.77% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -16.70% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 41.45% |
| 10 | Anika Therapeutics | 197.89 Mn | 131.10 Mn | 19.00 Mn | -16.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.28% |
| Dec 31, 2025 | 35.97% |
| Sep 30, 2025 | -8.04% |
| Jun 30, 2025 | -14.05% |
| Mar 31, 2025 | -14.79% |
| Dec 31, 2024 | -4.17% |
| Sep 30, 2024 | 1.10% |
| Jun 30, 2024 | -3.95% |
| Mar 31, 2024 | -6.59% |
| Dec 31, 2023 | -871.99% |
| Sep 30, 2023 | -16.98% |
| Jun 30, 2023 | -6.93% |
| Mar 31, 2023 | -31.68% |
| Dec 31, 2022 | -455.29% |
| Sep 30, 2022 | -13.32% |
| Jun 30, 2022 | -8.28% |
| Mar 31, 2022 | -10.11% |
| Dec 31, 2021 | -39.43% |
| Sep 30, 2021 | 3.17% |
| Jun 30, 2021 | 23.93% |